welcome to DuchenneXchange
- a positively charged Duchenne muscular dystrophy community.- join today!
- login
First Patient Dosed in Phase II Clinical Trial in Duchenne Muscular Dystrophy
Antisense Therapeutics today announced dosing of the first patient in a Phase II clinical trial of its immunomodulatory therapy, ATL1102, in patients with Duchenne Muscular Dystrophy (DMD).
Commencement of the trial represents an important development milestone for the Company and for patients seeking better and safer treatments.
ATL1102 is an inhibitor of CD49d expression on certain immune cells (T cells). DMD patients who have a greater number of T cells with high levels of CD49d on their surface have more severe and rapid disease progression.
rareRelated
-
Clinical Management of Duchenne Muscular Dystrophy: The State of the ArtIntroduction: Duchenne muscular dystrop...
-
Antisense Oligonucleotides for the Treatment of Cardiomyopathy in Duchenne Muscular DystrophyDuchenne muscular dystrophy (DMD) is an ...
-
Can a drug cure genetic disease? | Steve Wilton | TEDxPerthhttps://youtu.be/qgfwOuvMLrE...
-
Duchenne UK: DMD Patient and Caregiver Survey Resultshttps://www.youtube.com/watch?v=d2EpSB8R...
-
CoQ10 and Prednisone in Non-Ambulatory DMDThis study will help determine if CoQ10 ...
-
Ataluren: An Overview of Clinical Trial Results in Nonsense Mutation Duchenne Muscular DystrophyObjective: Provide an overview of atalu...
-
Clinical Trial to Evaluate the Efficacy, Safety, and Tolerability of RO7239361 in Ambulatory Boys With Duchenne Musc...This is a multi-center, randomized, doub...
